Tissue remodeling is an important feature of asthma. The latter is characterized by airway smooth muscle hypertrophy and a number of other changes, including subbasement membrane thickening, loss of epithelium, inflammatory cell infiltration, and goblet-cell hyperplasia. The exact mediators that cause these changes and their regulation are poorly understood.
Matrix metalloproteinases (MMPs) are zinc and calcium-dependent proteases that digest most extracellular matrix components. MMPs are produced by structural cells such as fibroblasts and endothelial and epithelial cells and by many inflammatory cells including macrophages, 1 eosinophils, 2 neutrophils, 3 and mast cells. 4 They are secreted as latent proenzymes and converted to the active form by proteolytic cleavage of an amino-terminal domain. 5 MMPs might be important in tissue remodeling in the airways through their ability to affect the integrity of the basal lamina and the degree of infiltration by inflammatory cells.
MMP-2 and MMP-9 have been shown to be important mediators of inflammation in a murine model of asthma 6 and in immune complex-mediated lung injury. 7 Biopsy specimens from asthmatic patients show abundant expression of MMP-9 messenger RNA by in situ hybridization. 2 This mRNA localized mostly in eosinophils. MMP-9 in the bronchoalveolar lavage fluid is higher in asthmatic patients 8 and in patients in status asthmaticus 9 than in normal control subjects. Significant levels of MMP-9 are also found in the sputum of asthmatic patients. 10 In addition, MMP-9 production by eosinophils is required for their transmigration through Matrigel monolayers in vitro. 11 Finally, gelatinases are also important for T-cell transmigration through the basal lamina. 12 These observations imply a significant role for MMPs in asthma, but the stimuli that induce their production during allergic inflammation are not known.
Airway epithelium plays an active role in inflammation through the production of a variety of lipid mediators, cytokines, chemokines, growth factors, and extracellular matrix components. Epithelial cells are also an important source of MMP-2 and MMP-9; the expression of the latter is upregulated by proinflammatory stimuli. 13, 14 Protease-activated receptor-2 (PAR-2) has been detected in many tissues, but its exact physiologic and pathophysiologic role is not clear. 15 Trypsin and mastcell tryptase 16 are the only proteases shown to activate PAR-2. There is evidence that PAR-2 activation is involved in inflammation. Inflammatory cytokines increase PAR-2 mRNA expression in human umbilical vein endothelial cells. 17 PAR-2 activation increases vascular permeability 18 and induces nitric oxide-mediated vasodilatation, 19, 20 hypotension, 19 leukocyte rolling, adhesion and extravasation, 21 and neurogenic inflammation. 22 Finally, PAR-2 activation can induce chemokine secretion. 23 However, PAR-2 receptors on airway epithelial cells have been shown to offer protection from bronchoconstriction. 24 We hypothesized that PAR-2 receptor activation also has proinflammatory effects in the airways. We found that PAR-2-mediated activation of airway epithelial cells induces MMP-9 release but not MMP-2, tissue inhibitors of metalloproteinase (TIMP)-1, or TIMP-2 release. We also showed that MMP-9 upregulation involved mitogenactivated protein kinase (MAP-kinase) and NFκB activation, was prostaglandin-independent, and was completely inhibited by corticosteroids.
MATERIAL AND METHODS Material
Pancreatic trypsin, dexamethasone, and MG-132 (Cbz-Leu-Leuleucinal; Sigma-Aldrich Canada LTD, Oakville, Ontario, Canada); recombinant human TNF (Cedarlane Laboratories Ltd, Ontario, Canada); Trizol, murine Moloney leukemia virus reverse transcriptase, Taq polymerase, oligo-dT primers, (Gibco BRL, Ontario, Canada); Fura-2 (Molecular Probes Inc, Eugene, Ore); Dulbecco's modified Eagle's medium (DMEM), FCS, penicillin, streptomycin, and L-glutamine (Biowhittaker, Walkersville, Md) were purchased as shown. Budesonide was generously provided by Astra Pharma Inc (Mississauga, Ontario, Canada).
The human pulmonary type II-like epithelial cell line A549 was acquired from the American Type Culture Collection (Rockville, Md); small airway epithelial cells (SAEC) that were isolated from human airways were purchased from Clonetics (Walkersville, Md).
PCR primers were synthesized by the DNA services laboratory, University of Alberta. PAR-l-, PAR-2-, and PAR-4-activating peptides (>95% pure by HPLC and mass spectrometry criteria) were synthesized by the Peptide Synthesis Facility of the Faculty of Medicine, University of Calgary. Two PAR-2-activating peptides (transcinnamoyl-LIGRLO-NH 2 or tc-LIGRLO-NH 2 and SLIGRL-NH 2 ) and 1 inactive peptide (LRGILS-NH 2 ) were used. The 2 peptides activate PAR-2 receptors with the same potency 25 and are thought not to activate other known PAR receptors. 26 The anti-PAR-2 rabbit polyclonal antiserum B5 was generated as previously described. 27 Airway epithelial cell culture and activation A549 cells were cultured in 12-well plates with DMEM supplemented with 10% FBS, 4 mmol/L L-glutamine, and 100 µg/mL penicillin/streptomycin until confluent. They were then maintained for 24 hours in DMEM without supplements and subsequently activated for 24 hours in DMEM with the indicated concentrations of PAR-2-activating peptides, trypsin, or TNF. Supernatants were collected, concentrated at ×10, and kept at -70°C until analyzed. Cells were either lysed in Tris-buffered saline solution (supplemented with 1% Triton X-100, 10 µg/mL aprotinin, 4 µg/mL leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride, and 5 mmol/L EDTA, pH 7.4) for zymography and Western blotting or solubilized in Trizol for RNA extraction.
SAEC were cultured in 12-well plates in serum-free medium supplemented with growth factors (30 µg/mL bovine pituitary extract, 0.5 µg/mL hydrocortisone, 0.5 ng/mL human recombinant epidermal growth factor, 0.5 µg/mL epinephrine, 10 µg/mL transferrin, 5 µg/mL insulin, 0.1 ng/mL retinoic acid, 6 ng/mL triiodothyronine, 50 µg/mL gentamicin, 50 ng/mL amphotericin B, and 0.5 mg/mL human epithelial growth factor) until they were 80% to 90% confluent and were maintained in DMEM without supplements for a further 48 hours. Cells were then activated in DMEM for 24 hours.
Corticosteroids, indomethacin, NFκB, and MAP-kinase inhibitors were added for 3 hours before A549 cell activation with PAR-2-activating peptides.
Ca ++ measurements
A549 cells were loaded with Fura-2 as described 28 and analyzed with a CAF-100 Ca ++ analyzer (Japan Spectroscopic Co LTD, Tokyo, Japan). Data were obtained with Virtual Bench (National Instrument Corporation, Austin, Texas) and analyzed with Excel (Microsoft Corporation, Redmond, Wash). The intracellular concentration of free Ca ++ was calculated as described. 29 
RT-PCR analysis
Total RNA was isolated from A549 cells with Trizol according to the manufacturer's instructions. PCR was performed with the following primers (0.4 µmmol/L concentration) for MMP-9 (5´-CGTGGA-GAGTCGAAATCTCTG-3´; 5´-CCAAACTGGATGACGATGTCT-3´), and MMP-2 (5´-CCCAAAACGGACAAAGAGTT-3´; 5´-ACTGTCTCTGGGTCCAGATCA-3´). The amplification of β2-microglobulin (5´-CTCGCGCTACTCTCTCTTTCTGG-3´; 5´-GCTTACATGTCTCGATCCGACTTAA-3´) was used to verify that equal amounts of RNA were used for reverse transcription and PCR amplification from different experimental conditions. The annealing temperature was 54°C for MMP-9 and MMP-2 and 58°C for β2-microglobulin. Amplified fragment sizes for β2-microglobulin, MMP-9, and MMP-2 were 335 bp, 331 bp, and 293 bp, respectively.
Gelatin zymography
SDS-PAGE gelatin zymography was performed with 7% polyacrylamide gels containing 2% gelatin. Phorbol myristate acetate-treated (100 nmol; 48 hours at 37°C) HT 1080 human fibrosarcoma cell supernatant was used as a positive control to identify gelatinolytic activity of proenzymes and active forms of MMP-2 and MMP-9. 30 After electrophoresis at 4°C, the gels were washed 3 times in 2% Triton X-100 at room temperature, incubated in 50 mmol/L Tris-HC1 buffer (pH 7.6, supplemented with 0.15 mol NaCl, 5 mmol/L CaCl 2 , and 0.05% NaN 3 ) at 37°C for 24 hours and then stained with 0.05% Coomassie Brilliant Blue G-250. Proteolytic activity was identified as clear bands on a blue background. 
Statistical analysis and optical density measurements

RESULTS
PAR-2 activation induces MMP-9 mRNA and enzymatic activity in A549 cells
Trypsin (10 U/mL) induced a sharp increase in the intracellular Ca ++ concentration in A549 cells (Fig l) , as did the PAR-2-activating peptide tc-LIGRLO-NH 2 (70 µmmol/L; Fig 1) . The inactive peptide LRGILS-NH 2 had no effect. Although treatment of the cells with trypsin desensitized the PAR-2 response to tc-LIGRLO-NH 2 (Fig 1) , pretreatment of the cells with tc-LIGRLO-NH 2 did not completely desensitize the cell calcium response to trypsin (Fig 1) but abolished the response to the subsequent application of tc-LIGRLO-NH 2 , which suggests that trypsin may also activate receptors other than PAR-2 on A549 cells. We verified the presence of PAR-2 receptors on A549 cells by flow cytometry using the rabbit polyclonal anti-PAR-2 antibody B5. These results document the presence of functional PAR-2 receptors on A549 cells. A549 cells expressed low levels of MMP-9 mRNA. The PAR-2-activating peptide tc-LIGRLO-NH 2 (70 µmmol/L) upregulated MMP-9 mRNA expression within 2 hours, and the mRNA levels remained significantly higher than in unstimulated cells for up to 24 hours (Fig 2, A) . TNF (100 ng/mL), known to induce MMP-9 in other systems, 31 also upregulated MMP-9 mRNA expression.
The PAR-2-activating peptide tc-LIGRLO-NH 2 , at concentrations between 7 and 70 µmmol/L, also induced a dose-dependent increase in pro-MMP-9 release from A549 cells (Fig 2, B) . The increase ranged from 6.5 ± 0.6-fold with 7 µmmol/L tc-LIGRLO-NH 2 to 71.7 ± 18.7-fold with 70 µmmol/L. The inactive peptide LRGILS-NH 2 had no effect on MMP-9 release. TNF (100 ng/mL) also upregulated pro-MMP-9 release (124.2 ± 53.8-fold). No active form of MMP-9 was released after PAR-2 activation. A second PAR-2-activating peptide, SLIGRL-NH 2 , had similar effects over the same concentration range (data not shown). Treatment with PAR-2-activating peptides or TNF had no effect on the level of PAR-2 expression on the surface of A549 or on the proliferation rate, under the culture conditions used. In all cases 2 to 2.5 × l0 5 cells (viability by trypan blue, >98%) were recovered from each well of the 12-well culture plates. Neither a highly specific PAR-1-activating peptide (AparafluoroFRCyclohexylACitY-NH 2 at 40 µmmol/L) nor a PAR-4-activating peptide (GYPGKF-NH 2 at 400 µmmol/L) induced MMP-9 release from A549 cells (data not shown).
A549 cells showed significant basal pro-MMP-2 release that did not change after activation with PAR-2-activating peptides or TNF (Fig 2, B) . Similarly, no change in MMP-2 mRNA was detected by RT-PCR (data not shown). MMP-2 or MMP-9 enzymatic activity was not observed in A549 cell lysates after 24 hours of incubation with or without PAR-2-activating peptides, which indicates that most of the MMP-9 enzymatic activity released after stimulation is newly synthesized protein.
MMP-9 activity is partly regulated by TIMPs. PAR-2 activation did not affect TIMP-1 or TIMP-2 release from A549 cells (data not shown). These results pointed to a selective upregulation of synthesis and release of MMP-9 after PAR-2-mediated activation of A549 epithelial cells.
MMP production by human SAEC and effects of PAR-2 activation
SAEC cells released pro-MMP-9, pro-MMP-2, and the active form of MMP-2. SAEC produced higher basal amounts of MMP-9 than A549 cells. MMP-9 production by SAEC was upregulated after activation with PAR-2-activating peptides or TNF (Fig 2, C) . The peptide tc-LIGRLO-NH 2 (18 µmmol/L) caused 56.3% ± 6.7% and TNF (100 ng/mL) caused 55.7% ± 4.7% increase of MMP-9 release compared with unstimulated cells. This effect was inhibited by approximately 30% after preincubation of SAEC with 10 -6 mmol budesonide. The amount of MMP-9 mRNA was also increased by more than 2.5- fold after 24 hours of incubation with PAR-2-activating peptides or TNF (Fig 2, D) . A smaller increase (approximately 1.5-fold) was seen at 4 hours and 8 hours.
Effect of corticosteroids on MMP-9 induction
Corticosteroids have been shown to inhibit the production of MMP-9 in other systems. To study the effect of dexamethasone on pro-MMP-9 release, we preincubated A549 cells for 3 hours with 10 -6 mmol dexamethasone before activating the cells as described earlier. Dexamethasone almost completely abolished the induction of MMP-9 release by the tc-LIGRLO-NH 2 or TNF (Fig 3, A) . Budesonide (a corticosteroid used in its inhaled form in patients with asthma) inhibited PAR-2-mediated pro-MMP-9 release by more than 70% at concentrations between 10 -6 and 10 -9 mmol and by 33% ± 6.9% at l0 -10 mmol (Fig 3, B) . Budesonide had the same effect on SLIGRL-NH 2 and on TNF-mediated pro-MMP-9 release (data not shown). This effect of budesonide was mediated through the downregulation of MMP-9 mRNA (Fig 3, C) . Dexamethasone and budesonide (10 -6 mmol) also decreased basal MMP-2 release from A549 cells (Fig 3, A and B) by 65.3% ± 10.9% (P < .02; n = 3 experiments) and 45.5% ± 7.8% (P < .001; n = 7 experiments), respectively.
Signal transduction pathways that induce MMP-9 release from A549 cells
PAR-2 activation induces prostaglandin production by airway epithelial cells, 24 and prostaglandins are known to mediate MMP-9 upregulation. 31, 32 The cyclooxygenase inhibitor indomethacin (10 -5 mmol) did not affect PAR-2-or TNF-mediated MMP-9 release (Fig 4, A) , which indicates that MMP-9 induction in our model is prostaglandin independent.
Because PAR-2 stimulation activates the MAP kinase pathway, 33 the inhibitor of MEK1, a kinase that is part of the MAP-kinase pathways, PD98059 was used. PD98059 (25 µmmol/L) inhibited PAR-2-mediated MMP-9 release by 87% ± 8.2% (Fig 4, B) . The same concentration of PD98059 had a lower (48.4% ± 2.62%) but still significant inhibitory effect on TNF-mediated MMP-9 release. The kinase p38 is also activated by TNF 34 and to a lesser extent by PAR-2 receptors. 33 The p38 inhibitor SB203580 (to 1 µmmol/L) had no effect on MMP-9 release induced by PAR-2 or TNF (data not shown), which indicates that p38 does not participate in the MMP-9 release from A549 cells.
Corticosteroids have been shown to mediate some of their functions through NFκB inhibition. 35 MG-132, a proteasome inhibitor shown to inhibit NFκB in A549 cells, 36 was used to examine NFκB involvement in PAR-2-mediated MMP-9 release. MG-132 (after 3 hours of preincubation) significantly inhibited PAR-2-mediated (70 µmmol/L tc-LIGRLO-NH 2 ) MMP-9 release (67.8% ± 5.4% at 50 µmmol/L) and to a lesser extent TNF-mediated (100 ng/mL) MMP-9 release (22.4% ± 3.4% at 50 µmmol/L ; Fig 4, B) . PD98059 together with MG-132 (10 µmmol/L each) caused over 90% inhibition of PAR-2-mediated MMP-9 release, which suggests that MAPkinase and NFκB pathways work in parallel. 
Trypsin effect on MMP-9 production
Pancreatic trypsin in concentrations between 0.1 and 2 U/mL (higher concentrations of trypsin induced the detachment of the cells from the culture surface) caused significant upregulation of both pro-MMP-2 and pro-MMP-9 (Fig 5, A) . Trypsin, at 0.5 U/mL, induced a 2.0 ± 0.4-fold increase in pro-MMP-2 release and an 8.1 ± 1.0-fold increase in pro-MMP-9 release (Fig 5, B) . When concentrations of trypsin higher than 0.5 U/mL were used, the release of pro-MMP-2 was very high in concentrated supernatants, which rendered the gel unsuitable for densitometry. Using unconcentrated A549 supernatants, we found that the strongest upregulation of pro-MMP-2 release was a 30.2 ± 5.8-fold with 2 U/mL of trypsin (data not shown). Trypsin also induced the release of at least 2 more proteins with gelatinolytic activity (Fig 5, A) . These results indicate that, in epithelial cells, the effect of trypsin on MMP release might also involve the activation of receptors other than PAR-2.
DISCUSSION
In this study, we demonstrated that PAR-2-mediated activation of airway epithelial cells upregulated the synthesis and release of pro-MMP-9. MMP-9 was secreted in the proenzyme form from epithelial cells after PAR-2 activation. Recently, PAR-2 activation has been shown to cause relaxation of airways that was mediated by the release of cyclooxygenase products from airway epithelium, 24 which indicates a protective role for airway epithelial cell PAR-2. Our results indicate that the effect of PAR-2-receptor activation in the airways might be more complicated.
PAR-2 expression is abundant in the lung and the airways, but the physiologic functions and the physiologic ligands that activate PAR-2 are poorly understood. Trypsin immunoreactivity has been identified in airway epithelium, 24, 37 and a trypsin-like protease was purified from human airways. 38 It is likely, but yet to be verified, that this airway-derived trypsin-like enzyme may be able to activate PAR-2 receptors. Mast-cell tryptase might be another protease to activate PAR-2 receptors 16 although there is evidence to suggest that it may activate only a subpopulation of PAR-2. 39 Mast cells, and in particular tryptase and TNF, have been implicated in the upregulation of MMPs. 40, 41 MMP release from airway epithelium, as a result of mast-cell activation, could facilitate inflammatory cell recruitment in the lung, particularly in the early stages of the inflammatory reaction when only a few inflammatory cells are present in these areas. Finally, many allergens are proteases, and at least 1 of them (Der p 9 from the house dust mite) can mediate some of its effects through trypsin-activated receptors. 42 These molecules, together with other unidentified proteases, could regulate the release of MMP-9 by the respiratory epithelium during allergic inflammation.
Trypsin upregulated not only the release of pro-MMP-9 but also the release of pro-MMP-2 and induced the release of at least 2 other proteins with gelatinolytic activity. This effect could be due to trypsin's ability to activate proteinase-activated receptors (PARs) other than PAR-2. The identity and nature of these receptors are not known, especially because PAR-1-and PAR-4-activating peptides had no effect on MMP release from A549 cells. The 2 other proteins with gelatinolytic activity could also represent proteolytic products of pro-MMP-9 after degradation by trypsin 43 or matrilysin, 44 which is also produced by airway epithelial cells. 45 Mast-cell tryptase appears to play an important role in respiratory disorders in which mast-cell activation is an important pathophysiologic feature, including asthma. 46, 47 Tryptase has also been implicated in the upregulation of MMP production. 40 We have evidence that tryptase induces MMP-9 release from airway epithelial cells, but its mode of action does not appear to be through PAR-2 activation (unpublished observations). This effect could be due to the inability of our tryptase preparation to activate PAR-2 receptors or to its ability to activate other receptors on epithelial cells with higher affinity. We are currently investigating in more detail the effects of tryptase on epithelial cell MMP release.
In addition to epithelial cells, PAR-2 is expressed in the airways by fibroblasts, smooth muscle cells, 24 and inflammatory cells, such as neutrophils, 48 which produce significant amounts of MMP-9. Whether PAR-2 activation on these cells can have a similar effect on MMP-9 production remains to be elucidated. However, airway epithelial cells may be the first cells to respond to PAR-2-activating enzymes, especially when these enzymes are inhaled as airborne allergens.
PAR-2 activation has been shown to induce prostaglandin-mediated effects in epithelial cells, 24 and induction of MMP-9 in some cases is prostaglandin dependent. 31 However, indomethacin, a prostaglandin synthase inhibitor, did not affect PAR-2-or TNF-mediated upregulation of MMP-9 release by epithelial cells. These results indicate that PAR-2 activation may have two independent effects on airway epithelial cells. It may induce prostaglandin release with the potential to mediate bronchodilation 24 or prostaglandin-independent proinflammatory mediator release.
Corticosteroids are used to modulate inflammation in asthma 49 and have the potential to inhibit the development of inflammatory changes in the lung. 50 Dexamethasone and budesonide inhibited PAR-2-mediated MMP-9 release from epithelial cells. Interestingly, both corticosteroids also inhibited the basal production of MMP-2 by airway epithelial cells. Corticosteroid treatment in asthmatic patients has been shown to decrease bronchoalveolar lavage MMP-9. 8 The effects of corticosteroids on MMP-9 release indicate that NFκB activation 35, 51 may be important for MMP-9 production. The proteasome inhibitor MG-132, which has been shown to inhibit NFκB in A549 epithelial cells, 36 decreased MMP-9 release by up to 40%. Together, these observations indicate that part of the antiinflammatory effects of corticosteroids may be mediated through the inhibition of MMP production in the airways.
PAR-2 receptors have been shown to activate the MAP-kinase pathway. 33 The MEK-1 inhibitor PD98059 caused more than 80% inhibition of PAR-2-mediated MMP-9 release from A549 cells. PD98059 has been shown to inhibit cyclooxygenase. 52 However, our results with indomethacin indicate that the inhibitory effect of PD98059 must be mediated through MAP-kinase inhibition. PAR-2 also activates p38 kinase, 33 but the p38 inhibitor SB203580 did not affect the PAR-2-mediated upregulation of MMP-9 release.
The observed MMP-9 induction by PAR-2 activation in epithelial cells implicates serine proteases (such as trypsin-like enzymes, mast-cell tryptase and allergen proteases) in inflammatory responses in the airways. The release of MMP might be one of the pathways through which local production and release of serine proteases can affect the inflammatory response in the lung.
